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Reply to Visit-to-Visit Blood Pressure Variation: Time to Reanalyze All The
Data From the TROPHY Study
To the Editor:
We are glad to see that 6 years after publication of the
Trial of Preventing Hypertension (TROPHY),1 the
results are still being debated. Only truly new and
important findings can elicit such an interest.
TROPHY reported more robust results in the first 2
than in the second 2 years of the study.1 Two years of
treatment with candesartan produced a 66.3% relative
risk reduction (RRR) of hypertension, and the treatment
was well tolerated. At the end of year 4, the RRR in the
group that had been switched from candesartan to
placebo at year 2 was highly significant but clinically
modest (15.6%). We stated that “we do not advocate
treatment of 25 million people with prehypertension
and that further studies are needed.” This call for action
was a smashing success. The Short Treatment with the
Angiotensin Receptor Blocker Candesartan Surveyed by
Telemedicine (STAR CAST) study in Japan will analyze
the reversal from stage 1 to prehypertension and is
nearly completed.2 The CHINON study in China3
recruited 10,000 patients and will compare cardiovas-
cular outcomes in active treatment and placebo groups.
In Brazil the Hypertension Prevention in Pre-Hyperten-
sive Individuals (PREVER) study4 evaluates the effect of
diuretic treatment in patients with prehypertension who
failed to respond to lifestyle modification.
In the meantime, we responded to an early critique of
TROPHY by reanalyzing data according to the Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure (JNC 7) definition of hypertension.5–7 In the
reanalysis, all original findings were confirmed5 and the
median time to hypertension as defined by JNC 7 was
4.0 years in the group previously randomized to cande-
sartan. Thus, according to current standards for initi-
ation of treatment, 50% of patients did not need to
resume medication up to 2 years after cessation of a 2-
year course of candesartan. We are disappointed that
this body of work had escaped Dr Schalkwyk’s and
Turner’s attention.
We have recently published a paper in this Journal on
the measurement of visit-to-visit variability of blood
pressure (BP) using data from the placebo arm of the
TROPHY trial.8 This work was intended to investigate
different approaches to the estimation of visit-to-visit
variability, an active area of BP research. The authors of
the letter note that the BP visit-to-visit variability is
higher in treated compared with the untreated patients,
referring to the results in Figure 1 of the article. Their
observation is what one would expect when BP is
treated; that is, the visit-to-visit variability for patients
initiating treatment for hypertension will be higher than
those not initiating treatment because of the effect of
treatment. For example, if a patient has systolic BP
readings of 143, 139, 145, and 146 mmHg at visits 1
through 4 without antihypertensive medication use
(pretreatment: standard deviation=3.1 mm Hg) and
134, 128, 135, and 132 mm Hg at visits 5 through 8
following antihypertensive medication initiation (post-
treatment: standard deviation=3.1 mm Hg), the overall
standard deviation will be 6.5 mm Hg, which more than
doubles from the actual value due to treatment effect.
When the effect of treatment is excluded, that is, the
post-treatment BP measures were censored, the vari-
ability in patients who initiated treatment vs patients
always untreated was similar (Figure 1).
TROPHY produced a rich set of data that we will
continue to analyze according to our sense of priorities.
We anticipate that ongoing trials will clarify many
questions that TROPHY could not resolve. However,
there is a need for additional studies. None of the
ongoing trials of prehypertension will discontinue active
treatment and thereafter evaluate incident hypertension.
We invite Drs Schalkwyk and Turner to join the
international community and design an Australian-
New Zealand study that could provide new insights
and verify or disprove their assumptions.
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